Protagenic Therapeutics, Inc. PTIX
0.65 USD +0.03 (+4.84%)
At closeNov 3, 2026, 4:00 PM EST
0.50 -0.15 -23.09%
After hours · Nov 3, 4:00 PM ET
0.65 Day range 0.66
0.128 52-week range 2.38
- YTD
- -50.00%
- 1 year
- -74.71%
- Market cap
- 1.18M
- EPS (ttm)
- 2.34
- Shares out
- 6.79M
- P/E ratio
- 0.28
- Forward P/E
- -0.92
- YTD return
- -50.00%
- 1-year return
- -74.71%
- Volume
- 1.00K
- Avg volume
- 11.93K
- Open
- 0.66
- Previous close
- 0.62
- Day's range
- 0.65 – 0.66
- 52-week range
- 0.128 – 2.38
- Beta
- 0.25
- Earnings date
- Aug 14, 2023
YTD -0.1200 (-16.22%)
Key statistics
- Enterprise value
- 1.84M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.65
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -3.12M
- Total cash
- 924.60K
- Total debt
- 0
- Return on equity
- -206.36%
- Short % of float
- 2.52%
- 50-day average
- 0.6005
- 200-day average
- 0.916195
Next earnings
Aug 14, 2023
Expected Aug 14, 2023. Consensus EPS estimate 0.00.
Financials — quick view
PTIX Revenue — quarterly 0
PTIX Net income — quarterly -869.50K
PTIX EPS — quarterly -0.47
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.14 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.36 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.39 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -0.38 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.32 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
About Protagenic Therapeutics, Inc.
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- protagenic.com
News
Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder 
Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model 
Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner 
Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114 
Contrasting Vanda Pharmaceuticals (NASDAQ:VNDA) and Atrinsic (NASDAQ:PTIX) 
Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 
Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market 
Atrinsic (NASDAQ:PTIX) Shares Up 10.9% – Should You Buy? 
Head-To-Head Contrast: Praxis Precision Medicines (NASDAQ:PRAX) versus Atrinsic (NASDAQ:PTIX) 
Protagenic Therapeutics Reports Topline Phase 1 Safety Data For PT00114, Was Well Tolerated Across All Dose Ranges Studied; Paves Way For Phase 2 In Stress-Related Neuropsychiatric Conditions
Your note
Sign in to keep a note on PTIX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARROW ALEXANDER K | Chief Financial Officer | Purchase | Oct 11, 2023 | 45,815 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Citadel Advisors Llc | 0.57% | 40,909 | 21.87K | Sep 29, 2024 |
| Vanguard Group Inc | 0.46% | 33,166 | 17.73K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.36% | 26,054 | 13.93K | Sep 29, 2024 |
| Osaic Holdings Inc | 0.30% | 21,414 | 11.45K | Sep 29, 2024 |
| State Street Corporation | 0.19% | 13,812 | 7.38K | Sep 29, 2024 |
| Virtu Financial LLC | 0.18% | 13,118 | 7.01K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.45% | 31,996 | 17.11K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.24% | 17,059 | 9.12K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.07% | 5,007 | 2.68K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 3,289 | 1.76K | Oct 30, 2024 |